

Predictors of long-term outcomes in patients treated with
thromboembolic pulmonary hypertension: data from the
long-term extension trial

Lancet Respiratory Medicine, the
4, 372-380

DOI: [10.1016/s2213-2600\(16\)30022-4](https://doi.org/10.1016/s2213-2600(16)30022-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Treatment of Chronic Thromboembolic Pulmonary Hypertension: The Role of Medical Therapy and Balloon Pulmonary Angioplasty. <i>Methodist DeBakey Cardiovascular Journal</i> , 2016, 12, 205-212.	0.5	10
2	Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 361-371.	5.2	97
3	Predictors of long-term survival in pulmonary hypertension. <i>Lancet Respiratory Medicine</i> , 2016, 4, 338-339.	5.2	1
4	Guanylate cyclase stimulators for pulmonary hypertension. <i>The Cochrane Library</i> , 2016, 2016, CD011205.	1.5	14
6	Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. <i>Respiratory Medicine</i> , 2017, 128, 50-56.	1.3	31
7	sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension. <i>Respiratory Medicine</i> , 2017, 122, S28-S34.	1.3	6
8	Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Respiratory Medicine</i> , 2017, 129, 124-129.	1.3	11
9	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1234-1242.	0.3	37
10	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. <i>European Respiratory Journal</i> , 2017, 49, 1602409.	3.1	178
11	Medical management of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Review</i> , 2017, 26, 160107.	3.0	52
12	An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. <i>European Respiratory Review</i> , 2017, 26, 160121.	3.0	156
13	The pathophysiology of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Review</i> , 2017, 26, 160112.	3.0	307
14	Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Review</i> , 2017, 26, 160111.	3.0	229
15	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 785-794.	5.2	201
16	The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study. <i>Pulmonary Circulation</i> , 2017, 7, 684-691.	0.8	10
17	Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences. <i>Respiratory Medicine Case Reports</i> , 2017, 22, 39-43.	0.2	11
18	Riociguat in PAH and CTEPH: Strategies for Patient Management. <i>Pulmonary Therapy</i> , 2017, 3, 31-43.	1.1	2
19	An Update on the Management of Chronic Thromboembolic Pulmonary Hypertension. <i>Current Problems in Cardiology</i> , 2017, 42, 7-38.	1.1	18

#	ARTICLE	IF	CITATIONS
20	Editorial Commentary: Chronic thromboembolic pulmonary hypertension evolves diagnostically and therapeutically. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 38-40.	2.3	0
21	2016, une année pas tout à fait comme les autres. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, S1-S3.	0.0	1
22	Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 1195-1207.	2.0	25
23	Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. <i>BMC Pulmonary Medicine</i> , 2017, 17, 216.	0.8	23
25	Prevention and treatment of the chronic thromboembolic pulmonary hypertension. <i>Thrombosis Research</i> , 2018, 164, 150-156.	0.8	4
26	REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 836-843.	0.3	29
27	From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators. <i>Biological Chemistry</i> , 2018, 399, 679-690.	1.2	62
28	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. <i>Pulmonary Circulation</i> , 2018, 8, 1-6.	0.8	54
29	Follow-up after acute Pulmonary Embolism. <i>Hamostaseologie</i> , 2018, 38, 22-32.	0.9	36
30	Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat. <i>Clinical Pharmacokinetics</i> , 2018, 57, 647-661.	1.6	43
31	Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V. <i>Current Problems in Cardiology</i> , 2018, 43, 217-231.	1.1	3
33	Soluble Guanylate Cyclase Stimulators and Activators. <i>Handbook of Experimental Pharmacology</i> , 2018, 264, 355-394.	0.9	104
34	Pulmonary endarterectomy and the cost of patient refusal. <i>European Respiratory Journal</i> , 2018, 52, 1801581.	3.1	2
35	Acute and Chronic Pulmonary Embolism: Perspectives on Diagnosis and Management. , 2018, , 355-366.		1
36	Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. <i>European Respiratory Journal</i> , 2018, 52, 1800248.	3.1	61
37	Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018, 272, 69-78.	0.8	140
38	Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-7.	0.8	44
39	The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2018, 52, 1800589.	3.1	87

#	ARTICLE	IF	CITATIONS
40	Chronic Thromboembolic Pulmonary Hypertension. <i>Clinics in Chest Medicine</i> , 2018, 39, 605-620.	0.8	19
41	Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study. <i>Clinical Respiratory Journal</i> , 2019, 13, 693-699.	0.6	7
43	Improved hemodynamics and cardiopulmonary function in patients with inoperable chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty. <i>Respiratory Research</i> , 2019, 20, 250.	1.4	38
45	Practical management of riociguat in patients with pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661986893.	1.0	6
46	Treprostinil for the treatment of chronic thromboembolic pulmonary hypertension. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 807-813.	1.0	1
47	A meta-analysis of randomized controlled trials in targeted treatments of chronic thromboembolic pulmonary hypertension. <i>Clinical Respiratory Journal</i> , 2019, 13, 467-479.	0.6	3
48	Advances in targeted therapy for chronic thromboembolic pulmonary hypertension. <i>Heart Failure Reviews</i> , 2019, 24, 949-965.	1.7	15
49	Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension. <i>IJC Heart and Vasculature</i> , 2019, 22, 163-168.	0.6	23
50	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1802004.	3.1	68
51	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). <i>Circulation Journal</i> , 2019, 83, 842-945.	0.7	132
52	Critical Care of Patients After Pulmonary Thromboendarterectomy. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2019, 33, 3110-3126.	0.6	7
53	Klippel-Trenaunay syndrome as a rare cause of chronic thromboembolic pulmonary hypertension. <i>Respiratory Medicine and Research</i> , 2019, 76, 48-53.	0.4	6
54	Chronic thromboembolic pulmonary hypertension (CTEPH): what do we know about it? A comprehensive review of the literature. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 159-168.	0.6	17
55	Correlation of native T1 mapping with right ventricular function and pulmonary haemodynamics in patients with chronic thromboembolic pulmonary hypertension before and after balloon pulmonary angioplasty. <i>European Radiology</i> , 2019, 29, 1565-1573.	2.3	28
56	Cardio-pulmonary MRI for detection of treatment response after a single BPA treatment session in CTEPH patients. <i>European Radiology</i> , 2019, 29, 1693-1702.	2.3	27
57	Chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801915.	3.1	607
58	Cyclophilin A as a biomarker for the therapeutic effect of balloon angioplasty in chronic thromboembolic pulmonary hypertension. <i>Journal of Cardiology</i> , 2020, 75, 415-423.	0.8	2
59	cGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 287-302.	1.4	82

#	ARTICLE	IF	CITATIONS
60	Chronic Thromboembolic Pulmonary Hypertension-Management Strategies and Outcomes. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 2513-2523.	0.6	15
61	Safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in real-world clinical practice: interim data from post-marketing surveillance in Japan. Pulmonary Circulation, 2020, 10, 1-9.	0.8	7
62	Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies. Pulmonary Circulation, 2020, 10, 204589402096383.	0.8	5
63	Long-term real world clinical outcomes of macitentan therapy in chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2020, 167, 105966.	1.3	6
64	Chronic thromboembolic pulmonary hypertension: interventional approaches. Heart, 2020, 106, 1525-1531.	1.2	2
65	Treatment of pulmonary hypertension with riociguat: a review of current evidence and future perspectives. Expert Opinion on Pharmacotherapy, 2020, 21, 1145-1155.	0.9	7
67	Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience. Open Heart, 2020, 7, e001144.	0.9	54
68	How should a physician approach the pharmacological management of chronic thromboembolic pulmonary hypertension?. Expert Opinion on Pharmacotherapy, 2021, 22, 557-563.	0.9	2
69	Riociguat: Clinical research and evolving role in therapy. British Journal of Clinical Pharmacology, 2021, 87, 2645-2662.	1.1	18
70	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220.	1.3	23
71	The preliminary diagnostic and therapeutic outcomes of chronic thromboembolic pulmonary hypertension registry rajaie cardiovascular medical and research center. Research in Cardiovascular Medicine, 2021, 10, 29.	0.2	0
72	Treatment effect prediction using CT after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. European Radiology, 2021, 31, 5524-5532.	2.3	1
73	Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2021, 177, 106293.	1.3	11
74	Balloon Pulmonary Angioplasty: State of the Art. Interventional Cardiology Review, 2020, 16, e02.	0.7	19
75	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241.	1.3	13
76	Advanced Surgical and Percutaneous Approaches to Pulmonary Vascular Disease. Clinics in Chest Medicine, 2021, 42, 143-154.	0.8	0
77	Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Medicina (Lithuania), 2021, 57, 355.	0.8	6
78	Risk prediction in medically treated chronic thromboembolic pulmonary hypertension. BMC Pulmonary Medicine, 2021, 21, 128.	0.8	5

#	ARTICLE	IF	CITATIONS
79	Evolution of randomized, controlled studies of medical therapy in chronic thromboembolic pulmonary hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-8.	0.8	2
80	Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension. <i>Medicine (United States)</i> , 2021, 100, e26211.	0.4	2
81	Segurança e eficácia da angioplastia pulmonar por balão em Portugal num centro de referência em hipertensão pulmonar. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 727-738.	0.2	2
82	Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study. <i>ERJ Open Research</i> , 2021, 7, 00082-2021.	1.1	3
83	Chronic thromboembolic pulmonary hypertension anno 2021. <i>Current Opinion in Cardiology</i> , 2021, 36, 711-719.	0.8	4
84	Hipertensão pulmonar tromboembólica crônica: experiência inicial de doentes submetidos a tromboendarterectomia pulmonar. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 741-752.	0.2	3
85	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1301-1326.	0.3	36
86	Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1172-1180.	0.3	9
87	Pulmonary arterial hypertension specific therapy: The old and the new. , 2020, 214, 107576.		38
89	Pulmonary Hypertension. <i>Deutsches A&#x0308;rztblatt International</i> , 2017, 114, 73-84.	0.6	87
90	Clinical Updates on the Diagnosis and Management of Chronic Thromboembolic Pulmonary Hypertension. <i>Annals of the Academy of Medicine, Singapore</i> , 2020, 49, 320-330.	0.2	3
91	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 106-119.	0.6	17
92	Soluble GC stimulators and activators: Past, present and future. <i>British Journal of Pharmacology</i> , 2021, , .	2.7	45
93	Chronic thromboembolic pulmonary hypertension after an acute pulmonary embolism: fundamental concepts of diagnosis and review of current treatment options. <i>Russian Journal of Cardiology</i> , 2021, 26, 4588.	0.4	0
95	Drug demand satisfaction of patients with idiopathic pulmonary arterial hypertension. <i>Pacific Medical Journal</i> , 2019, , 18-22.	0.0	0
96	Clinical and economic evaluation of the effectiveness of the use of Riociguat for the treatment of patients with inoperable, recurrent or persistent chronic thromboembolic pulmonary hypertension under the conditions of the Republic of Kazakhstan. <i>International Professional Journal Medicine</i> , 2020. 3-4. 8-16.	0.0	0
97	Safety and efficacy of balloon pulmonary angioplasty in a Portuguese pulmonary hypertension expert center. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 727-737.	0.2	1
98	Akute und chronische Lungenembolie. , 2020, , 281-293.		0

#	ARTICLE	IF	CITATIONS
99	Perioperative Management of Pulmonary Hypertension. A Review. <i>The Journal of Critical Care Medicine</i> , 2021, 7, 83-96.	0.3	6
100	Chronic thromboembolic pulmonary hypertension - still evolving. <i>Global Cardiology Science & Practice</i> , 2020, 2020, e202011.	0.3	1
101	Successful use of intravenous treprostinil as a bridge to pulmonary thromboendarterectomy. <i>BMJ Case Reports</i> , 2021, 14, .	0.2	0
102	Chronic thromboembolic pulmonary hypertension: Initial experience of patients undergoing pulmonary thromboendarterectomy. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 741-752.	0.2	1
103	Chronic thromboembolic pulmonary hypertension “ still evolving. <i>Global Cardiology Science & Practice</i> , 2020, 2020, e202011.	0.3	4
104	Advances in treatment of chronic thromboembolic pulmonary hypertension. <i>Thrombosis Research</i> , 2022, 212, 30-37.	0.8	3
105	Successful use of intravenous treprostinil as a bridge to pulmonary thromboendarterectomy. <i>BMJ Case Reports</i> , 2021, 14, e235806.	0.2	0
106	Prognostic Value of Pulmonary Artery Pulsatility Index in Right Ventricle Failure-Related Mortality in Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of Clinical Medicine</i> , 2022, 11, 2735.	1.0	0
107	Chronic Thromboembolic Pulmonary Hypertension. <i>Lung</i> , 2022, 200, 283-299.	1.4	8
108	Chronic thromboembolic pulmonary hypertension: from pathogenesis to the choice of treatment tactics. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 791-796.	0.2	2
109	Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 961-971.	5.2	73
110	Medical and interventional therapies for inoperable CTEPH: a necessary combination?. <i>Lancet Respiratory Medicine</i> , 2022, 10, 926-927.	5.2	3
111	Hemodynamic indices in pulmonary hypertension: a narrative review. <i>Cardiovascular Diagnosis and Therapy</i> , 2022, 12, 693-707.	0.7	4
112	Long-term outcome prediction for chronic thromboembolic pulmonary hypertension after pulmonary endarterectomy. <i>Clinical Cardiology</i> , 2022, 45, 1255-1263.	0.7	2
113	Riociguat inhibits ultra large VWF string formation on pulmonary artery endothelial cells from chronic thromboembolic pulmonary hypertension patients. <i>Pulmonary Circulation</i> , 0, , .	0.8	0
115	Design, synthesis and biological evaluation of new 3,4-dihydroquinoxalin-2(1H)-one derivatives as soluble guanylyl cyclase (sGC) activators. <i>Heliyon</i> , 2022, 8, e11438.	1.4	0
116	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension concomitant with Klippel-Trenaunay-Weber Syndrome. <i>Pulmonary Circulation</i> , 0, , .	0.8	2
117	Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review of the Most Updated Literature. <i>Journal of Clinical Medicine</i> , 2022, 11, 6976.	1.0	3

#	ARTICLE	IF	CITATIONS
118	A Comprehensive Assessment of Right Ventricular Function in Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of Clinical Medicine</i> , 2023, 12, 47.	1.0	5
119	Riociguat real-world use in patients with chronic thromboembolic pulmonary hypertension: A retrospective, observational cohort study in France. <i>Respiratory Medicine and Research</i> , 2023, 83, 100987.	0.4	0
120	Soluble guanylate cyclase stimulator riociguat in the palette of modern specific therapy for precapillary pulmonary hypertension: from the pathophysiological basis to the results of current research. <i>Systemic Hypertension</i> , 2023, 19, 45-52.	0.1	0
121	Balloon pulmonary angioplasty: are we there yet? Lessons learned and unanswered questions. <i>Breathe</i> , 2022, 18, 220217.	0.6	1